CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling

Published:2019-08-30 Issue:10 Volume:20 Page:
ISSN:1469-221X
Container-title:EMBO reports
language:en
Short-container-title:EMBO Rep

Author:

Choi Hee‐Joo¹²,Jin Sora²,Cho Hani²,Won Hee‐Young²,An Hee Woon²,Jeong Ga‐Young²,Park Young‐Un²,Kim Hyung‐Yong²,Park Mi Kyung³,Son Taekwon⁴,Min Kyueng‐Whan²^ORCID,Jang Ki‐Seok²,Oh Young‐Ha²,Lee Jeong‐Yeon⁵^ORCID,Kong Gu¹²^ORCID

Affiliation:

1. Institute for Bioengineering and Biopharmaceutical Research (IBBR) Hanyang University Seoul Korea

2. Department of Pathology College of Medicine Hanyang University Seoul Korea

3. National Cancer Center Goyang Korea

4. College of Pharmacy Seoul National University Seoul Korea

5. Department of Medicine College of Medicine Hanyang University Seoul Korea

Funder

National Research Foundation of Korea

Publisher

EMBO

Subject

Genetics,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/embr.201948058

Reference58 articles.

1. Targeting HER2 for the Treatment of Breast Cancer

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

4. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

5. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The anti‐tumor effects of cosmosiin through regulating AhR/CYP1A1‐PPARγ in breast cancer;The FASEB Journal;2024-08-20

2. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis;Gastric Cancer;2024-05-23

3. Paclitaxel Overload Supramolecular Oxidative Stress Nanoamplifier with a CDK12 Inhibitor for Enhanced Cancer Therapy;Biomacromolecules;2024-05-23

4. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance;The Oncologist;2024-04-04

5. Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study;The Oncologist;2024-03-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3